The price of weight loss treatment has shifted more in the past 12 months than in the prior decade. Here's what everything actually costs right now — and what's coming next.
Self-pay GLP-1 prices have dropped 30–60% from their peaks. The Wegovy pill starts at $149/month. TrumpRx.gov connects patients to manufacturer programs at $250–350/month for injectables. Generic Qsymia is available at $50–100/month. And Medicare coverage at $50/month copay launches July 2026. The cost barrier, while still real, is narrowing fast.
| Medication | List Price | Self-Pay/Best Price | Weight Loss |
|---|---|---|---|
| Tirzepatide (Zepbound) | $1,000+/mo | $199–449/mo (LillyDirect) | 20–22.5% |
| Semaglutide injection (Wegovy) | $1,349/mo | $199–349/mo (NovoCare) | 15–17% |
| Semaglutide pill (Wegovy oral) | TBD | $149–299/mo (NovoCare) | ~15% |
| TrumpRx.gov (brand GLP-1) | N/A | $250–350/mo injectable, $149 pill | 15–22% |
| Telehealth GLP-1 programs | N/A | $149–400/mo all-inclusive | 15–22% |
| Qsymia (generic) | $200+/mo | $50–100/mo | 7–10% |
| Contrave | $400–800/mo | $99/mo (CurAccess) | 5–6% |
| Phentermine (generic) | N/A | $10–50/mo | 5–7% |
| Metformin (generic, off-label) | N/A | $4–20/mo | 2–6% |
| Orlistat / Alli (OTC) | N/A | $30–60/mo | 3–5% |
The biggest pricing story of 2025–2026 is the manufacturer self-pay revolution. Facing pressure from compounded alternatives and Congressional scrutiny, both Novo Nordisk and Eli Lilly launched direct-to-patient pricing that undercuts the inflated list prices by 50–80%.
NovoCare Pharmacy: Wegovy injection at $349/month ($199 for the first two months). Wegovy pill starting at $149/month for the 1.5 mg dose, up to $299 at the maintenance dose. No insurance required — these are pure self-pay prices.
LillyDirect: Zepbound starting at $199/month for the lowest dose, up to $449 for the maintenance dose. Available through Lilly's direct pharmacy channel. When orforglipron is approved, Lilly has announced self-pay pricing starting at $149.
TrumpRx.gov: The government's self-pay portal doesn't sell drugs directly but connects patients to manufacturer discount programs. Average monthly cost for injectable GLP-1s starts around $350, expected to fall to $250 within two years. GLP-1 pills start at $149.
Novo Nordisk has announced a list price reduction to $675/month across all semaglutide products, effective January 1, 2027. This is significant because list prices drive insurance formulary decisions. Lower list prices typically mean broader insurance coverage, lower copays for insured patients, and better negotiated rates for pharmacy benefit managers. This won't directly change self-pay pricing (which is already below $675), but it should meaningfully improve insurance access throughout 2027.
See current pricing and promotional offers on semaglutide and tirzepatide programs. All-inclusive telehealth — no hidden fees.
See Current Pricing →Insurance coverage is moving in two directions simultaneously. Roughly 55% of large employers now cover GLP-1s for obesity (up from ~40% in 2024), according to J.P. Morgan and Mercer data. That's the good news. The bad news: some insurers are pulling back. Blue Cross Blue Shield of Massachusetts stopped covering GLP-1s for obesity in 2026, citing premium impact. Other plans have tightened eligibility requirements — requiring BMI 40+ instead of 30+, or mandating step therapy through cheaper medications first.
If your insurance covers weight loss medication, you'll typically pay a copay of $25–100/month. But prior authorization is almost universal, and 30–40% of first requests are denied. Appeals often succeed — especially when your provider documents failed prior weight loss attempts and obesity-related comorbidities.
The Medicare GLP-1 Bridge launches July 1, 2026, with a $50/month copay for eligible beneficiaries (BMI ≥35 or BMI ≥30 with comorbidities). This is a short-term payment demonstration running through December 31, 2026. The full BALANCE Model Part D coverage begins January 1, 2027, pending manufacturer negotiations and plan participation. For the 42% of adults 60+ with obesity, this represents a transformational shift in access. See our complete Medicare GLP-1 coverage guide.
Compounded semaglutide and tirzepatide products at $99–299/month attracted millions of patients during the 2022–2025 shortage era. In 2026, the calculus has changed. The FDA has ended enforcement discretion for compounding (503A pharmacies as of April 2025, 503B outsourcing facilities as of May 2025 for semaglutide). Warning letters and DOJ referrals are accelerating. And brand-name self-pay prices have dropped close to compounded pricing — Wegovy pill at $149, injectable at $199–349.
Patients currently on compounded GLP-1s should have a conversation with their provider about transitioning to FDA-approved products. See our guide to compounded semaglutide safety in 2026.
For most self-pay patients in 2026, the best value path is: start with the Wegovy pill at $149/month (lowest dose), titrate up to see your response, and switch to an injectable only if the oral form doesn't meet your goals. For maximum effectiveness at the lowest cost, telehealth GLP-1 programs bundle everything (consultation, medication, shipping) at $149–400/month. Use HSA/FSA funds to pay with pre-tax dollars. Check your employer plan annually — coverage is expanding. And if you're over 65 with Medicare Part D, mark your calendar for July 2026.
Competitive pricing on weight loss medication programs. Quick consultations with licensed providers.
Check Current Pricing →Several developments will push prices lower through the rest of 2026 and into 2027:
GLP-1 weight loss programs with clear cost breakdowns. Licensed providers across multiple health categories.
View Pricing →